Zuranolone
Zurzuvae (zuranolone) is a small molecule pharmaceutical. Zuranolone was first approved as Zurzuvae on 2023-10-31. It is used to treat postpartum depression in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| mental disorders | D001523 |
Trade Name
FDA
EMA
Zurzuvae
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zurzuvae | New Drug Application | 2024-07-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postpartum depression | EFO_0007453 | D019052 | F53.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ZURANOLONE, ZURZUVAE, BIOGEN INC | |||
| 2028-10-31 | NCE | ||
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 1 | 2 | 8 | — | — | 11 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | 2 | 8 | — | — | 11 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 1 | 2 | 6 | — | — | 9 |
| Postpartum depression | D019052 | EFO_0007453 | F53.0 | — | — | 2 | — | — | 2 |
| Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | — | — | — | 1 |
| Essential tremor | D020329 | EFO_0003108 | G25.0 | — | 1 | — | — | — | 1 |
| Tremor | D014202 | HP_0001337 | R25.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zuranolone |
| INN | zuranolone |
| Description | Zuranolone is a 3-hydroxy steroid that is 5beta-19-norpregnane substituted by hydroxy, methyl, oxo, and 4-cyano-1H-pyrazol-1-yl groups at positions 3, 3, 20 and 21, respectively. It is a positive allosteric modulator of GABAA receptor developed by Sage Therapeutics and Biogen for the treatment of postpartum depression in adults. It has a role as an antidepressant, a GABA modulator and an anticonvulsant. It is a nitrile, a member of pyrazoles, a 3-hydroxy steroid and a 20-oxo steroid. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12CC[C@@H]3[C@H]4CC[C@@](C)(O)C[C@H]4CC[C@H]3[C@@H]1CC[C@@H]2C(=O)Cn1cc(C#N)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 1632051-40-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4105630 |
| ChEBI ID | — |
| PubChem CID | 86294073 |
| DrugBank | DB15490 |
| UNII ID | 7ZW49N180B (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zurzuvae – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 184 documents
View more details
Safety
Black-box Warning
Black-box warning for: Zurzuvae
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
56 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use